HTA Philippines EXTENDS this call for proposals until 18 November 2025 (Tuesday)

Interested researchers shall submit requirements to htaresearch@dost.gov.ph.

The Health Technology Assessment (HTA) Philippines invites interested researchers to express interest and submit capsule proposals under the 2025 HTA Topics – Batch 1 Call [HTA General Track – Cycle 1 and Cycle 2 Clinical assessments; Pre-Cycle 1, Cycle 1, and Cycle 2 topics for Economic and ELSHI Assessments]

The following are the health technology topics for assessments to be funded under this Call for Capsule Proposals:

HTA Topics for Clinical Assessment

1. Ibuprofen intravenous (IV) infusion for the management of mild to moderate pain, and as an adjunct to opioid analgesics for the management of moderate to severe pain in pediatric patients six (6) months and older
2. Sentosa SQ HIV Genotyping Assay for the diagnosis or detection of HIV subtypes and genetic variants in people living with HIV
3. Chemotherapeutic agents (e.g. mitomycin C, doxorubicin, epirubicin, cisplatin) used in transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma

HTA Topics for Economic Assessment

A. For Cost-Effectiveness/Utility Analysis (CEA/CUA) + Budget Impact Analysis (BIA) + Household Financial Impact (HFI) Analysis

1. Trastuzumab emtansine (100 mg or 160 mg powder for concentrate for solution for IV infusion) compared to trastuzumab alone, and trastuzumab plus pertuzumab for adjuvant treatment of people with human epidermal growth factor 2 positive (HER2+) early breast cancer with residual invasive disease after neoadjuvant treatment
2. Tirofiban in combination with heparin compared to usual care [e.g., unfractionated or low-molecular weight heparin (alone), aspirin, clopidogrel] among patients aged > 19 years old with coronary ischemic syndromes (CIS) undergoing coronary angioplasty or atherectomy
3. Human papillomavirus (HPV) vaccine 9-valent (types 6, 11, 16, 18, 31, 33, 45, 52, 58) [Recombinant vaccine, 0.5mL suspension for intramuscular injection in 1.5 mL syringe; 0.5 mL single-dose vial] compared to 2-3 doses of 2-valent and 4-valent HPV vaccines for prevention of HPV-related infection and cancer in females and males, 9 years old and onwards

B. For Cost-Minimization Analysis (CMA) + BIA + HFI Analysis

• Paliperidone palmitate every 3 months (PP3M) compared to paliperidone palmitate every month (PP1M) among adult patients with schizophrenia who have been adequately treated with PP1M for at least four months

HTA Topics for Ethical, Legal, Social, and Health Systems Impact (ELSHI) Assessment

1. Tirofiban in combination with heparin compared to usual care [e.g., unfractionated or low-molecular weight heparin (alone), aspirin, clopidogrel] among patients aged > 19 years old with coronary ischemic syndromes (CIS) undergoing coronary angioplasty or atherectomy
2. Paliperidone palmitate every three months (PP3M) compared to Paliperidone palmitate 1-month (PP1M) among adult patients with schizophrenia who have been adequately treated with PP1M for at least four months
3. Human papillomavirus (HPV) vaccine 9-valent (types 6, 11, 16, 18, 31, 33, 45, 52, 58) [Recombinant vaccine, 0.5mL suspension for intramuscular injection in 1.5 mL syringe; 0.5 mL single-dose via] compared to 2-3 doses of 2-valent and 4-valent HPV vaccines for prevention of HPV-related infection and cancer in females and males, 9 years old and older

For interested researchers, kindly take note of the following important dates:

• Deadline of expression of interest: 24 October 2025 (Friday)
• Deadline for submission of requirements: 10 working days from the submission of the expression of interest

Submissions shall be sent to htaresearch@dost.gov.ph

Kindly see the call guide and Terms of Reference for more info:

Call Guide:

Links to Terms of Reference:

Topic Assessment	Link to TOR
Clinical Assessment	2025_Clinical-topics_Ibuprofen_Sentosa_Chemo-drugs_TOR
Economic Assessment	[2025 CEA_CUA topics] EE TOR Batch 4 [Updated 2025 CMA topics] PP3M TOR as of 05Nov2025
ELSHI Assessment	[Updated 2025 ELSHI topics] PP3M, Nonavalent, and Tirofiban TOR (as of 06 Nov 2025)